ONECUT2 is a driver of neuroendocrine prostate cancer
Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/15eb3a591377407ab3aae62e9aca95cb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:15eb3a591377407ab3aae62e9aca95cb |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:15eb3a591377407ab3aae62e9aca95cb2021-12-02T16:57:34ZONECUT2 is a driver of neuroendocrine prostate cancer10.1038/s41467-018-08133-62041-1723https://doaj.org/article/15eb3a591377407ab3aae62e9aca95cb2019-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-018-08133-6https://doaj.org/toc/2041-1723Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, and find hypoxia directed therapy to be effective in NEPC.Haiyang GuoXinpei CiMusaddeque AhmedJunjie Tony HuaFraser SoaresDong LinLoredana PucaAram VosoughiHui XueEstelle LiPeiran SuSujun ChenTran NguyenYi LiangYuzhe ZhangXin XuJing XuAnjali V. SheahanWail Ba-AlawiSi ZhangOsman MahamudRavi N. VellankiMartin GleaveRobert G. BristowBenjamin Haibe-KainsJohn T. PoirierCharles M. RudinMing-Sound TsaoBradly G. WoutersLadan FazliFelix Y. FengLeigh EllisTheo van der KwastAlejandro BerlinMarianne KoritzinskyPaul C. BoutrosAmina ZoubeidiHimisha BeltranYuzhuo WangHousheng Hansen HeNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-13 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Haiyang Guo Xinpei Ci Musaddeque Ahmed Junjie Tony Hua Fraser Soares Dong Lin Loredana Puca Aram Vosoughi Hui Xue Estelle Li Peiran Su Sujun Chen Tran Nguyen Yi Liang Yuzhe Zhang Xin Xu Jing Xu Anjali V. Sheahan Wail Ba-Alawi Si Zhang Osman Mahamud Ravi N. Vellanki Martin Gleave Robert G. Bristow Benjamin Haibe-Kains John T. Poirier Charles M. Rudin Ming-Sound Tsao Bradly G. Wouters Ladan Fazli Felix Y. Feng Leigh Ellis Theo van der Kwast Alejandro Berlin Marianne Koritzinsky Paul C. Boutros Amina Zoubeidi Himisha Beltran Yuzhuo Wang Housheng Hansen He ONECUT2 is a driver of neuroendocrine prostate cancer |
| description |
Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, and find hypoxia directed therapy to be effective in NEPC. |
| format |
article |
| author |
Haiyang Guo Xinpei Ci Musaddeque Ahmed Junjie Tony Hua Fraser Soares Dong Lin Loredana Puca Aram Vosoughi Hui Xue Estelle Li Peiran Su Sujun Chen Tran Nguyen Yi Liang Yuzhe Zhang Xin Xu Jing Xu Anjali V. Sheahan Wail Ba-Alawi Si Zhang Osman Mahamud Ravi N. Vellanki Martin Gleave Robert G. Bristow Benjamin Haibe-Kains John T. Poirier Charles M. Rudin Ming-Sound Tsao Bradly G. Wouters Ladan Fazli Felix Y. Feng Leigh Ellis Theo van der Kwast Alejandro Berlin Marianne Koritzinsky Paul C. Boutros Amina Zoubeidi Himisha Beltran Yuzhuo Wang Housheng Hansen He |
| author_facet |
Haiyang Guo Xinpei Ci Musaddeque Ahmed Junjie Tony Hua Fraser Soares Dong Lin Loredana Puca Aram Vosoughi Hui Xue Estelle Li Peiran Su Sujun Chen Tran Nguyen Yi Liang Yuzhe Zhang Xin Xu Jing Xu Anjali V. Sheahan Wail Ba-Alawi Si Zhang Osman Mahamud Ravi N. Vellanki Martin Gleave Robert G. Bristow Benjamin Haibe-Kains John T. Poirier Charles M. Rudin Ming-Sound Tsao Bradly G. Wouters Ladan Fazli Felix Y. Feng Leigh Ellis Theo van der Kwast Alejandro Berlin Marianne Koritzinsky Paul C. Boutros Amina Zoubeidi Himisha Beltran Yuzhuo Wang Housheng Hansen He |
| author_sort |
Haiyang Guo |
| title |
ONECUT2 is a driver of neuroendocrine prostate cancer |
| title_short |
ONECUT2 is a driver of neuroendocrine prostate cancer |
| title_full |
ONECUT2 is a driver of neuroendocrine prostate cancer |
| title_fullStr |
ONECUT2 is a driver of neuroendocrine prostate cancer |
| title_full_unstemmed |
ONECUT2 is a driver of neuroendocrine prostate cancer |
| title_sort |
onecut2 is a driver of neuroendocrine prostate cancer |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/15eb3a591377407ab3aae62e9aca95cb |
| work_keys_str_mv |
AT haiyangguo onecut2isadriverofneuroendocrineprostatecancer AT xinpeici onecut2isadriverofneuroendocrineprostatecancer AT musaddequeahmed onecut2isadriverofneuroendocrineprostatecancer AT junjietonyhua onecut2isadriverofneuroendocrineprostatecancer AT frasersoares onecut2isadriverofneuroendocrineprostatecancer AT donglin onecut2isadriverofneuroendocrineprostatecancer AT loredanapuca onecut2isadriverofneuroendocrineprostatecancer AT aramvosoughi onecut2isadriverofneuroendocrineprostatecancer AT huixue onecut2isadriverofneuroendocrineprostatecancer AT estelleli onecut2isadriverofneuroendocrineprostatecancer AT peiransu onecut2isadriverofneuroendocrineprostatecancer AT sujunchen onecut2isadriverofneuroendocrineprostatecancer AT trannguyen onecut2isadriverofneuroendocrineprostatecancer AT yiliang onecut2isadriverofneuroendocrineprostatecancer AT yuzhezhang onecut2isadriverofneuroendocrineprostatecancer AT xinxu onecut2isadriverofneuroendocrineprostatecancer AT jingxu onecut2isadriverofneuroendocrineprostatecancer AT anjalivsheahan onecut2isadriverofneuroendocrineprostatecancer AT wailbaalawi onecut2isadriverofneuroendocrineprostatecancer AT sizhang onecut2isadriverofneuroendocrineprostatecancer AT osmanmahamud onecut2isadriverofneuroendocrineprostatecancer AT ravinvellanki onecut2isadriverofneuroendocrineprostatecancer AT martingleave onecut2isadriverofneuroendocrineprostatecancer AT robertgbristow onecut2isadriverofneuroendocrineprostatecancer AT benjaminhaibekains onecut2isadriverofneuroendocrineprostatecancer AT johntpoirier onecut2isadriverofneuroendocrineprostatecancer AT charlesmrudin onecut2isadriverofneuroendocrineprostatecancer AT mingsoundtsao onecut2isadriverofneuroendocrineprostatecancer AT bradlygwouters onecut2isadriverofneuroendocrineprostatecancer AT ladanfazli onecut2isadriverofneuroendocrineprostatecancer AT felixyfeng onecut2isadriverofneuroendocrineprostatecancer AT leighellis onecut2isadriverofneuroendocrineprostatecancer AT theovanderkwast onecut2isadriverofneuroendocrineprostatecancer AT alejandroberlin onecut2isadriverofneuroendocrineprostatecancer AT mariannekoritzinsky onecut2isadriverofneuroendocrineprostatecancer AT paulcboutros onecut2isadriverofneuroendocrineprostatecancer AT aminazoubeidi onecut2isadriverofneuroendocrineprostatecancer AT himishabeltran onecut2isadriverofneuroendocrineprostatecancer AT yuzhuowang onecut2isadriverofneuroendocrineprostatecancer AT houshenghansenhe onecut2isadriverofneuroendocrineprostatecancer |
| _version_ |
1718382488297930752 |